via EPFL
Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant.
Their findings are published in the prestigious journal Cell Reports.
The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.
In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.
CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.
Treatment or prophylaxy
This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe.
The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.
Original Article: Scientists discover a highly potent antibody against SARS-CoV-2
More from: École Polytechnique Fédérale de Lausanne | Lausanne University Hospital
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Monoclonal antibody
- Experimental vaccine targets portions of the flu virus that don't change
Duke researchers have opened a new avenue in the attack against influenza viruses by creating a vaccine that encourages the immune system to target a portion of the virus surface that is less variable ...
- Another Monoclonal Antibody Delays Diabetes in Mouse Study
Johns Hopkins researchers have shown that a monoclonal antibody can reverse type 1 diabetes. It targets a different antigen than Tzield.
- CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight
Kuick Recent Published Report Highlights Ongoing Clinical Developments In CD70 Targeting Therapies LandscapeDelhi, May 01, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity & ...
- New monoclonal antibody vaccine slashes malaria risk in children
A recent study demonstrates that the monoclonal antibody-based vaccine L9LS is safe for children aged 6 to 10 and significantly reduces the risk of malaria infection and clinical symptoms by 70% and ...
- New Strategy Could Lead to Universal, Long-Lasting Flu Shot
“If we took your blood to see if are you likely to be protected from a strain of flu, we'd be measuring what your antibodies do to hemagglutinin as the best metric of what's likely to happen to you.
Go deeper with Google Headlines on:
Monoclonal antibody
[google_news title=”” keyword=”monoclonal antibody” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
SARS-CoV-2 monoclonal antibody
- Longest-Ever COVID Infection Lasted More Than 600 Days
A Dutch man with lymphoma and other blood disorders was infected with the COVID-causing virus for nearly two years, during which time the pathogen evolved numerous mutations ...
- How B cells recognize new variants of SARS-CoV-2
B cells are part of the immune system's memory. Their memories of previous infections or vaccinations provide the template for antibodies that have a protective effect the next time they come into ...
- SARS-CoV-2 Omicron Detection Antibodies
The Omicron (B.1.1.529) strain is by far the most divergent SARS-CoV-2 variant. It is critical to re-evaluate the ... Spike and Nucleocapsid proteins and validated all available antibodies against the ...
- Researchers employ microfluidic diffusional sizing characterize neutralizing antibody affinity to SARS-CoV-2
Affinity measurement was obtained through a contrived sample and buffer using recombinant SARS-CoV-2 RBD and monoclonal antibody. Limited saliva samples demonstrated that MDS applies to saliva ...
- SARS-CoV-2 related research products: Proteins, antibodies and more
ACROBiosystems closely monitors the development of the epidemic situation and expediting the development of SARS-COV-2 antigen proteins, antibodies, kits and other associated products to ...
Go deeper with Google Headlines on:
SARS-CoV-2 monoclonal antibody
[google_news title=”” keyword=”SARS-CoV-2 monoclonal antibody” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]